Category: <span>immunotherapy for mesothelioma</span>

Category: immunotherapy for mesothelioma

Atezolizumab, bladder cancer drug for mesothelioma, immunotherapy for mesothelioma, keytruda for mesothelioma, Mesothelioma News, opdivo for mesothelioma, Tecentriq

Tecentriq Raises Hope of New Mesothelioma Clinical Trial

 

The FDA recently approved immunotherapy drug Tecentriq (atezolizumab) for certain bladder and non-small cell lung cancers, raising hopes for a mesothelioma-specific clinical trial in 2017. Tecentriq, a product of Genentech Oncology, is following the path of Keytruda (pembrolizumab) and Opdivo (nivolumab) as drugs that target a specific protein blocking a body’s immune system from attacking…

The post Tecentriq Raises Hope of New Mesothelioma Clinical Trial appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

clinical trials for mesothelioma, first line treatment for mesothelioma, immunotherapy for mesothelioma, Keytruda, Mesothelioma News, Pembrolizumab, pleural mesothelioma treatment

Using Keytruda for Mesothelioma May Become a Reality

 

The U.S. Food and Drug Administration recently upgraded its approval of pembrolizumab (Keytruda) for metastatic non-small cell lung cancer, inching it closer to becoming an accepted treatment option for pleural mesothelioma. Pembrolizumab, produced by pharmaceutical giant Merck & Co., also is marketed as Keytruda. The FDA’s announcement last week converted its previous “accelerated” approval in…

The post Using Keytruda for Mesothelioma May Become a Reality appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

chemotherapy for mesothelioma, immunotherapy for mesothelioma, malignant pleural mesothelioma treatment, Mesothelioma News, second line mesothelioma treatment, sellas life sciences group, wt1 vaccine

FDA Speeds Possible Second-Line Treatment for Mesothelioma

 

The U.S. Food and Drug Administration awarded Fast Track designation recently to the WT1 cancer vaccine, moving it closer to becoming the first approved second-line treatment for malignant pleural mesothelioma. The vaccine, also known as galinpepimut-S, is an immunotherapy agent that targets the WT1 protein, which is expressed in high levels in various cancers, such…

The post FDA Speeds Possible Second-Line Treatment for Mesothelioma appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

clinical trial, Immunotherapy, immunotherapy clinical trial, immunotherapy for mesothelioma, Mesothelioma News, Mesothelioma Research, Mesothelioma treatment, raffitt hassan

Immunotherapy Trial for Mesothelioma Shows Early Promise

 

The immunotherapy drug avelumab showed promising results in a recent phase I clinical trial for malignant mesothelioma, raising hopes as a future second-line therapy. The clinical trial included 53 patients with pleural or peritoneal mesothelioma. It was part of the JAVELIN development program for avelumab, a series of clinical studies testing the drug on about…

The post Immunotherapy Trial for Mesothelioma Shows Early Promise appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.